Thomas Leist, MD

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.

Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.

Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.

MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.

Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.

Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.

Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved.

Experts in MS discuss the evolution in treatment options over time and the shift towards use of early high-efficacy therapy.

Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.